Takeda wants to work with Chinese partners to bring China innovation global

In the next decade, Japan’s largest drugmaker Takeda Pharma (TYO: 4502) is hoping to bring more Chinese developed drugs to the global market by working with local partners in some key therapeutic areas, said its leaders at Takeda R&D China innovation forum held in Shanghai.

“Takeda wants to unleash the full potential of China’s market and we will do three things to achieve that,” said Takeda China president Sean Shan.

One is that Takeda plans to build computer power to find digital solutions for patients in China. The Tokyo-based pharma is already exploring such solutions in Japan. For example, it is developing a digital twin technology for patients with Crohn’s disease. This technology aims to simulate multiple treatment options on the digital model made from data of an individual patient and predict prognosis of each option.